Recurrent pregnancy loss, defi ned as two or more spontaneous abortions, aff ects ‫%5ف‬ of all women of reproductive age. Epidemiological studies suggest that inherited and acquired thrombophilia of the mother, such as that caused by the Leiden polymorphism in blood coagulation factor V, contributes to the pathogenesis of fetal loss, as well as other adverse pregnancy outcomes (1-3). These studies also demonstrate a high study-to-study variability of association strength, suggesting the existence of as yet uncharacterized risk modifi ers. The pathogenesis of thrombophilia-associated fetal loss remains to be established. Evaluation of placental pathologies has not revealed a clear correlation between the prothrombotic status of the mother and the presence of villous infarcts, blood clots, or fi brin deposits in the placenta (4, 5), raising the question of whether thrombotic processes are indeed causative in thrombophilia-associated fetal loss or constitute an epiphenomenon. On the other hand, clinical trials suggest that heparin anticoagulation may indeed mitigate pregnancy failure in prothrombotic women (6-9). In view of the uncertain etiology of thrombophilia-associated pregnancy failure and the lack of established criteria for a more precise risk stratifi cation enabling identifi cation of truly at-risk pregnancies, the prophylactic anticoagulation of asymptomatic women and the risk-to-benefi t balance of anticoagulation therapy during pregnancy are subjects of intense debate (10-12).
Recurrent pregnancy loss, defi ned as two or more spontaneous abortions, aff ects ‫%5ف‬ of all women of reproductive age. Epidemiological studies suggest that inherited and acquired thrombophilia of the mother, such as that caused by the Leiden polymorphism in blood coagulation factor V, contributes to the pathogenesis of fetal loss, as well as other adverse pregnancy outcomes (1) (2) (3) . These studies also demonstrate a high study-to-study variability of association strength, suggesting the existence of as yet uncharacterized risk modifi ers. The pathogenesis of thrombophilia-associated fetal loss remains to be established. Evaluation of placental pathologies has not revealed a clear correlation between the prothrombotic status of the mother and the presence of villous infarcts, blood clots, or fi brin deposits in the placenta (4, 5) , raising the question of whether thrombotic processes are indeed causative in thrombophilia-associated fetal loss or constitute an epiphenomenon. On the other hand, clinical trials suggest that heparin anticoagulation may indeed mitigate pregnancy failure in prothrombotic women (6) (7) (8) (9) . In view of the uncertain etiology of thrombophilia-associated pregnancy failure and the lack of established criteria for a more precise risk stratifi cation enabling identifi cation of truly at-risk pregnancies, the prophylactic anticoagulation of asymptomatic women and the risk-to-benefi t balance of anticoagulation therapy during pregnancy are subjects of intense debate (10) (11) (12) .
Factor V Leiden (FvL) polymorphism, which renders coagulation factor V refractory to inactivating proteolysis by activated protein C, has been associated with both early (fi rst trimester) and late fetal loss in women (2) . In experimental mouse models homozygous status for the FvL polymorphism elicits pronounced thrombophilia but is not associated with intrauterine fetal loss or impaired fecundity (13) . In contrast, observations in animals lacking the receptor components of the protein C anticoagulant pathway,
Fetal gene defects precipitate plateletmediated pregnancy failure in factor V Leiden mothers
We describe a mouse model of fetal loss in factor V Leiden (FvL) mothers in which fetal loss is triggered when the maternal prothrombotic state coincides with fetal gene defects that reduce activation of the protein C anticoagulant pathway within the placenta. Fetal loss is caused by disruption of placental morphogenesis at the stage of labyrinth layer formation and occurs in the absence of overt placental thrombosis, infarction, or perfusion defects. Platelet depletion or elimination of protease-activated receptor 4 (Par4) from the mother allows normal placentation and prevents fetal loss. These fi ndings establish a cause-effect relationship for the observed epidemiologic association between maternal FvL status and fetal loss and identify fetal gene defects as risk modifi ers of pregnancy failure in prothrombotic mothers. Pregnancy failure is mediated by Par4-dependent activation of maternal platelets at the fetomaternal interface and likely involves a pathogenic pathway independent of occlusive thrombosis. Our results further demonstrate that the interaction of two given thrombosis risk factors produces markedly disparate consequences on disease manifestation (i.e., thrombosis or pregnancy loss), depending on the vascular bed in which this interaction occurs.
thrombomodulin (Thbd) and the endothelial protein C receptor (Procr), demonstrate that the integrity of this pathway within the placenta is essential for the maintenance of pregnancy (14) (15) (16) . Thbd-or Procr-knockout mice die in utero because of a placental malfunction that results from a lack of these receptors on zygote-derived trophoblast cells that line the passage of maternal circulation in the placenta. Importantly, fetal loss in these animal models occurs in the absence of maternal thrombophilia, and the relevance of these knockout models for fetal loss in thrombophilic mothers remains unclear.
In this paper, we test the hypothesis that the hemostatic balance in the placental vasculature is determined by the combination of maternal and fetal factors, which cooperatively regulate the activity of the coagulation system at the interface of maternal blood and fetal trophoblasts. We test and demonstrate this eff ect in a mouse model of pregnancy disorder in FvL mothers in which fetal loss is triggered by a combination of maternal and fetal prothrombotic defects. We exploit this model to identify risk modifi ers of fetal loss associated with maternal FvL status and to characterize the pathogenic mechanism underlying pregnancy failure.
RESULTS

Development of an animal model of fetal loss associated with maternal thrombophilia
Two genetically altered strains of mice were used: mice with APC resistance caused by the FvL polymorphism (13) and Thbd Pro mice with a reduced ability to activate protein C zymogen (17) . Both strains are viable in the homozygous state for the mutated allele and exhibit biochemical evidence of chronic, low-grade thrombin generation leading to enhanced fi brin deposition in multiple tissues but do not develop spontaneous thrombosis on a C57BL/6 genetic background. Homozygous Fv QQ and Thbd ProPro mice exhibit normal fertility and fecundity (13, 17) . These two strains of mice were intercrossed to produce Fv QQ Thbd Pro+ females in which we could assess pregnancy outcome as a function of Thbd expression on fetal trophoblast cells.
Off These results show that (a) fetal loss occurs in female mice with a latent prothrombotic state caused by homozygous status for either the Fv Q or the Thbd Pro allele; (b) the penetrance of fetal loss phenotype in these prothrombotic mothers is increased by reduced fetal Thbd function; and (c) the combination of the same risk factors within vascular compartments other than the placenta is compatible with normal development and hemostasis. p-values were calculated by χ 2 analysis using the expected numbers based on Mendelian inheritance. *, P < 0.0003; **, P < 0.04; # , P < 0.02. n, total number of pups analyzed.
ARTICLE
Disparate consequences of thrombosis risk factor interactions in the placenta and nonplacental vascular beds
To extend our fi ndings on Thbd function in pregnancy to additional, putative risk modifi ers of fetal loss, we investigated how reduced tissue factor pathway inhibitor (Tfpi) and Procr function on fetal trophoblast cells aff ect pregnancy outcomes in FvL mothers. Genetic suppression of tissue factormediated procoagulant activity expressed by trophoblast cells prevents the intrauterine loss of Thbd −/− , as well as Procr −/− embryos, suggesting that the level of tissue factor inhibition by Tfpi on trophoblast cells may be a critical modulator of the risk of fetal loss in prothrombotic mothers (15, 16 
In conclusion, reduced Tfpi expression at the bloodtrophoblast interface within the placental vascular bed does not signifi cantly increase the risk of pregnancy failure in FvL mothers.
Procr, like Tfpi, is coexpressed with Thbd by fetal trophoblast cells (19) and facilitates Thbd-mediated activation of protein C. To examine whether reduced Procr expression by trophoblast cells causes pregnancy failure in FvL mothers, we used "low Procr" mice (i.e., homozygous Procr δδ ). These mice exhibit severely reduced Procr expression yet develop and reproduce normally (20) . Fv Q+ Procr δδ pups were signifi cantly underrepresented in the off spring of Fv QQ Procr δ+ females mated to Procr δδ males (5 Fv Q+ Procr δδ vs. 18 Fv Q+ Procr δ+ ; n = 23; P < 0.007). In contrast, intercrosses of Fv Q+ Procr δδ mice yielded normal frequencies of Fv Q+ Procr δδ and Fv QQ Procr δδ pups (12 Fv Q+ Procr δδ , 5 Fv QQ Procr δδ , and 4 Fv ++ Procr δδ ; n = 21), which remained completely viable and normal as adults. Therefore, akin to the Thbd Pro mutation, reduced fetal Procr expression increases the risk of pregnancy failure in homozygous FvL mothers, whereas the same interaction does not produce a thrombotic pathology within the systemic vasculature.
Placental pathology of pregnancy failure in FvL females
Progeny from Fv QQ Thbd Pro+ intercrosses were analyzed at E10.5, E12.5, and E17.5 to determine the time of pregnancy p-values were calculated by χ 2 analysis using the expected numbers based on Mendelian inheritance. *, P < 0.004. Embryos in advanced stages of degradation were excluded from the analysis. n, total number of pups analyzed.
failure and the associated pathology of Fv QQ Thbd ProPro embryos (Table II) . Seven out of nine Fv QQ Thbd ProPro embryos were resorbed or severely developmentally retarded by E10.5; only one Thbd ProPro embryo was present at E12.5, and none were at E17.5 (Table II) . In timed pregnancies of Fv QQ Thbd Pro+ females mated to Thbd ProPro males (Table II) , Fv Q+ Thbd ProPro embryos were present in normal numbers at E9.5, but some of these were already smaller or delayed in developmental progress at this time ( Fig. 1, a and Fig. 2 and Fig. 3, a and b) . The smaller placental size could be attributed to a failure to form or expand the labyrinth layer of the placenta (Fig. 3, c-f) . At E9.5, the placenta of all retarded Thbd ProPro embryos (n = 8) had undergone chorioallantoic fusion, but the chorioallantoic surface had remained fl at with little or no branching and an absence of fetal and maternal vessel in-growths, resulting in a distinct lack of a well-formed labyrinth layer. Of note, the same defect in labyrinth formation was also observed in three out of six placentas of apparently normal Thbd ProPro embryos, indicating that the observed placental pathology precedes embryonic growth retardation. The placentas of other normal-appearing Thbd ProPro embryos had begun branching morphogenesis to form a labyrinth and appeared similar to placentas of Thbd Pro+ littermates. This observation, together with the observed survival of occasional Thbd ProPro embryos to a late developmental stage (E12.5), suggests that the defect may be in progression rather than in the initiation of chorioallantoic morphogenesis. Thrombi identifi ed by hematoxylin and eosin staining were validated by immunostaining with fibrin(ogen) and with p-selectin antibodies identifying platelet aggregates (Fig. 4) . Spiral arteries within the deciduas were free of thrombi in wild-type and mutant fetoplacental units (not depicted). To detect blood perfusion defects secondary to potential blood clots in vessels not included in our survey and to rule out other causes of impaired blood supply to the placenta, FITCdextran was injected in the maternal circulation. The fl uorescent tracer accumulated in the placenta of wild-type pregnancies in a characteristic ring-like structure formed by maternal blood in the labyrinth. Congruent with the developmental retardation and anatomical absence of labyrinth, this structure was absent in the placenta of Thbd ProPro embryos (Fig. 5) . FITC-dextran could, however, be readily visualized in decidual and placental blood spaces in FV QQ Thbd Pro+ mothers irrespective of embryonic genotype. These data support the notion that fetal loss in the described mouse model cannot be attributed to occlusive thrombosis and impaired perfusion of the placenta.
Fetal loss in FvL mice is mediated by the protease-activated receptor 4 (Par4) on maternal platelets
We examined the role of platelets in the pregnancy disorder of FvL mothers by immunodepleting maternal platelets with anti-GP1bα antibodies. Platelet depletion initiated at E7. 5 
D I S C U S S I O N
Our fi ndings reveal several new aspects of the association between maternal thrombophilia and fetal loss. First, it lends direct experimental support to the notion that the FvL carrier status of the mother increases the risk of pregnancy failure, thereby establishing a cause-eff ect relationship for the epidemiologic association. Second, it demonstrates that hemostatic regulators on fetal trophoblast cells are dominant risk modifi ers of fetal loss in FvL carriers. Thbd and Procr, allelic variants of which are suspected risk modifi ers in human thrombophilia (21) (22) (23) (24) (25) , are experimentally validated in the current mouse model as modulators of pregnancy success in FvL mothers. The experimental demonstration of a synergistic adverse eff ect of maternal and fetal prothrombotic mutations in causing pregnancy failure has direct implications for the risk stratifi cation of patient populations. It also validates the approach taken in the "NOHA fi rst" study (26) , which systematically includes analysis of the paternal (in lieu of the fetal) genome to more accurately interpret the epidemiological association between maternal thrombophilia and fetal loss. Third, it establishes a novel and unique animal model of fetal loss associated with maternal inherited thrombophilia. Using this animal model, we have identifi ed the Par4 receptor on maternal platelets as a key component of the pathogenic mechanism underlying fetal loss in FvL mice and have determined that, at least in mice, fetal loss occurs in the absence of overt thrombosis. The relevance of our observations for human FvL carriers remains to be determined.
Based on placental pathology, the pathogenesis of FvLassociated fetal loss in mice appears distinct from the complement-driven mechanism operating in fetal loss induced by antiphospholipid antibodies (27) . Consistent with this notion, platelet depletion did not ameliorate fetal loss in the antiphospholipid model, and anti-C5 antibody treatment was insuffi cient to rescue fetal loss in the FvL model (unpublished data).
In striking contrast to fetal loss caused by reduced function or expression of Thbd or Procr on trophoblast cells in FvL mothers, the combination of the same risk factors does not cause acute thrombosis in the systemic vasculature. The reverse is true for Tfpi, where lethal thrombosis ensues when heterozygous Tfpi defi ciency is combined with FvL homozygosity in the same animal (18) but is inconsequential with respect to pregnancy outcome. The absence of a measurable consequence of embryonic Tfpi heterozygosity on pregnancy outcome in FvL mothers may refl ect a substantial contribution of maternally derived plasma Tfpi in local hemostasis at the fetomaternal interface. Collectively, these observations demonstrate a marked discrepancy of consequences (i.e., thrombosis vs. pregnancy loss) triggered by the interaction of thrombosis risk factors in diff erent vascular beds and suggest that the eff ect of a given risk modifi er on venous or arterial thrombosis is not necessarily predictive of pregnancy outcome.
The placental abnormalities of embryos with reduced Thbd activity carried by FvL mothers and those associated with Thbd-null embryos (15) share characteristic features suggestive of a common underlying pathogenic mechanism. Both occur in the absence of overt thrombosis. Embryos with reduced Thbd activity in FvL mothers can be rescued by platelet depletion at E7.5 but not at E9.5, indicating that the pathogenic insult has already occurred by E9.5. Growth retardation of Thbd-null embryos is observed as early as E8.5, suggesting a similar time of pathogenic insult. In both cases, placental morphogenesis is disrupted at the time of labyrinth layer formation. The combined results from the analysis of fetal loss in these two models suggest that the expression of tissue factor on placental trophoblast cells provides a constitutive procoagulant stimulus in the placental vascular bed (15, 19) . The protein C anticoagulant pathway sustained by expression of Thbd and Procr on trophoblast cells appears to be necessary to suppress this stimulus. Localized disruption of this pathway at the fetomaternal interface-either caused by the complete lack of Thbd or Procr from trophoblast cells or a combination of fetal and maternal risk factors-permits amplifi cation of the coagulation reaction and formation of activated clotting factors, including thrombin. We fi nd that platelets and Par4 are critical mediators of placental failure. The impairment of placental growth and morphogenesis is therefore caused by a process similar to the initial tissue factorand thrombin-dependent stages of arterial thrombosis, likely involving platelet activation, but does not require thrombotic occlusion. Possible explanations for the lack of occlusive thrombi in the setting of an active coagulation cascade include inhibition of ADP-driven platelet aggregation caused by abundant expression of ecto-ATPDase/CD39 on the trophoblast cell surface (19) .
The nature of the mechanism by which activation of maternal platelets causes pregnancy failure is unknown, but the possibility that platelet-released factors negatively infl uence placental development or function is an obvious candidate. Peptide mediators with (anti)angiogenic activity have been suggested to alter trophoblast function and contribute to the etiology of pregnancy disorders such as preeclampsia (28) (29) (30) . Of note, platelets have been shown to adhere to endovascular trophoblasts within the lumen of spiral arteries in normal pregnancy (30) , indicating that the recruitment of platelets to the fetomaternal interface is a physiological process that links platelet function to the regulation of placental development.
It is noteworthy that fetal loss in FvL animals occurs in the absence of overt thrombosis in the mother's systemic vasculature and is caused by a highly localized defect precipitated by the fetal genotype, which aff ects individual placental beds. Local dysregulation of the protein C anticoagulant pathway at the fetomaternal interface alone (Thbd −/− embryos) is also suffi cient to cause fetal loss in a mother with nearnormal hemostatic function (Thbd +/− mothers) (15) . Complete disruption of the protein C pathway (≤3% of protein C), on the other hand, is accompanied by active thrombotic disease, consumptive coagulopathy, and a severe proinfl ammatory phenotype (31) . These animals suff er fetal genotypeindependent early pregnancy loss (E6.5) with a markedly diff erent disease etiology caused by the pronounced secondary eff ects of acute protein C defi ciency in the mother. Increasing maternal protein C to 18% of wild-type levels overcomes systemic thrombosis and infl ammation and restores normal pregnancies (31) .
In summary, we have presented animal models of placental malfunction and fetal loss secondary to inherited defects in the protein C anticoagulant pathway, including a clinically relevant gene defect (FvL) in the mother. The loss of Thbd ProPro embryos in FvL mothers correlates with the early fetal loss observed in women with the Leiden mutation. We also observed a partial loss of embryos with a heterozygous defect in Thbd function (Thbd Pro+ ) later in pregnancy (around E12.5, correlating with Leiden-associated late fetal loss in women) that we did not characterize further in this study. The early fetal loss in FvL mice is preceded by disrupted placental growth and morphogenesis during developmental events that lead to the formation of a functional labyrinth and is mediated through a platelet and Par4 receptor-driven mechanism but does not involve formation of occlusive thrombi in the placenta. The described animal model of thrombophilia-associated fetal loss provides an opportunity to test the effi cacy of antithrombotic treatments and, possibly, of antiplatelet treatments targeting the recruitment and activation of platelets in the placental vascular bed. (13, 17, 20, 32) . These mice were maintained on C57BL/6 genetic background.
MATERIALS AND METHODS
Mice
Histology. Embryonic development was assessed from dpc, assuming midday of plug as 0.5 dpc, and as previously described (15) . Dissections were performed, and pictures of embryos were taken under a microscope (SMZ-U; Nikon) equipped with a color camera (SPOT Insight; Diagnostic Instruments) and SPOT software (version 3.2.4; Diagnostic Instruments). 7-μm serial sections of formalin-fi xed (Sigma-Aldrich), paraffi n-embedded tissues were stained with hematoxylin and eosin for general morphology, identification of thrombi, and morphometric analysis. Thrombi were validated by immunostaining with antibodies that recognize fi brinogen (DakoCytomation) and p-selectin (Santa Cruz Biotechnology, Inc.). Immunostaining with antibodies against cytokeratin (DakoCytomation) was done after antigen retrieval with 40 μg/ml proteinase K in 10 mM Tris, pH 7.5, at 37°C for 30 min. ImageJ software (version 1.36b; National Institutes of Health) was used for morphometric analysis. Sizes of the decidua and placenta were measured on every 30th section, and the totals were used to arrive at decidua/ placenta ratio.
Perfusion studies and TAT and D-dimer measurements. Placental perfusion was examined by injecting pregnant females with 100 μl of 25 mg/ml FITC-labeled dextran (mol wt 200 × 10 4 ; Sigma-Aldrich) via the tail vein at 9.5 dpc. After 15 min, the uteroplacental units were dissected under a microscope (SteREO Discovery.V12 PentaFluar S; Carl Zeiss MicroImaging, Inc.) equipped with a GFP fi lter cube (excitation, BP470/40; emission, BP525/50) and a camera (Axiocam MRc5; Carl Zeiss MicroImaging, Inc.). The fetal aspect of the placenta was photographed using Axiovision software (version 4.5; Carl Zeiss MicroImaging, Inc.). The uteroplacental units were embedded in tissue-freezing medium (Triangle Biomedical Sciences) and fl ash frozen in a dry ice-ethanol bath. Serial sections of the frozen units were examined and photographed under a microscope (Eclipse TE200; Nikon) equipped with a camera (Photometrics CoolSNAP ES; Roper Scientifi c, Inc.) using Metamorph software (version 6.2r6; Universal Imaging Corp.). D-dimer and TAT levels were measured as previously described (33) .
Platelet depletions.
For platelet depletion, a mixture of anti-GPIbα rat monoclonal antibodies (34) or polyclonal nonimmune IgG (control; R300 or C301, Emfret Analytics) was injected via the tail vein at 4 μg/g body weight. Anti-GPIbα antibodies depleted 95% of the platelets within 1 h, as counted manually and with an automated cell counter (ABX Diagnostics). Injections were repeated on the fourth day.
Statistical analysis. The signifi cance of survival diff erences between groups was determined using the χ 2 analysis. The Student's t test (two-tailed with unequal variance) was used for all other statistical analysis. P < 0.05 was considered signifi cant.
